Gu Xueyuan, Ding Jianxun, Zhang Zhiyu, Li Qin, Zhuang Xiuli, Chen Xuesi
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P.R. China.
Curr Pharm Des. 2015;21(36):5187-97. doi: 10.2174/1381612821666150923095618.
Osteosarcoma (OS) is one of the most serious malignancies along with a high incidence in children and teenagers. Although the neoadjuvant chemotherapy of OS has made great progress and prolongs the five-year survival rates of patients to some extent, drugs are restrained from clinical application due to the unsatisfactory efficacy and severe side effects, especially for the systemic therapy through intravenous injection. The polymeric nanoparticles as anti-cancer drug nanocarriers make OS treatment more promising and effective. Specifically, various polymeric nanoparticles have been developed to overcome the difficulties in targeting delivery of drugs to OS tissue and/or cells through passive and/or active strategies. This review presents an overview on the development of polymeric nanoparticles for anti-cancer drug delivery in OS treatment, and briefly describes the challenge and opportunity for future development.
骨肉瘤(OS)是最严重的恶性肿瘤之一,在儿童和青少年中发病率很高。尽管骨肉瘤的新辅助化疗取得了很大进展,并在一定程度上提高了患者的五年生存率,但由于疗效不理想和副作用严重,药物在临床应用中受到限制,尤其是静脉注射的全身治疗。作为抗癌药物纳米载体的聚合物纳米颗粒使骨肉瘤治疗更具前景和有效性。具体而言,已经开发出各种聚合物纳米颗粒,通过被动和/或主动策略克服了将药物靶向递送至骨肉瘤组织和/或细胞的困难。本文综述了用于骨肉瘤治疗中抗癌药物递送的聚合物纳米颗粒的发展概况,并简要描述了未来发展面临的挑战和机遇。